RN1201 injection for newly diagnosed multiple myeloma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called RN1201 as a first-line treatment for multiple myeloma, a blood cancer. The study aims to see if it is safe and effective for patients who have never been treated for this condition before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with multiple myeloma and have a specific marker called BCMA on your cancer cells
- You are between 18 and 70 years old
- Your liver and kidney function are mostly normal (based on blood tests)
- Your heart is working well with an ejection fraction of at least 50% and no fluid around the heart
- You are well enough to care for yourself with minimal help (ECOG score 0–2)
- You can commit to all study visits and follow the treatment plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called RN1201 for people with a high-risk type of multiple myeloma. It’s designed to target two specific markers on myeloma cells (BCMA and CD19) and may be given after initial treatment to help keep the cancer from coming back.
This early-stage trial tests a new therapy called RN9101 for multiple myeloma that has come back or stopped responding to previous treatments. The drug targets a specific protein (BCMA) on myeloma cells and may help patients whose disease has progressed despite earlier therapies.
This trial tests a new immunotherapy, RN1201, for people with certain blood cancers (like multiple myeloma, leukemia, or lymphoma) that have come back or not responded to standard treatments. It aims to see if this treatment can help when other options have stopped working.
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two proteins on myeloma cells (BCMA and GPRC5D). It is for people with multiple myeloma that has come back or stopped responding to at least three prior treatments.
This trial tests an experimental therapy using immune cells (CAR-NK cells) designed to target and kill cancer cells in people with multiple myeloma or plasma cell leukemia that has returned or stopped responding to treatment. The goal is to see if it is safe and effective.
This trial tests a new treatment using your own immune cells, called CAR-NK cells, to fight multiple myeloma that has not responded to at least two prior treatments. The cells are designed to target a protein called BCMA on myeloma cells, potentially offering a new option for people with relapsed or refractory disease.
Hear when a new Multiple Myloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.